These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22684563)

  • 1. Mechanisms of prostate atrophy after LHRH antagonist cetrorelix injection: an experimental study in a rat model of benign prostatic hyperplasia.
    Yang D; Hou T; Yang X; Ma Y; Wang L; Li B
    J Huazhong Univ Sci Technolog Med Sci; 2012 Jun; 32(3):389-395. PubMed ID: 22684563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Halmos G; Perez R; Fernandez JB; Vidaurre I; Szalontay L
    Prostate; 2011 May; 71(7):736-47. PubMed ID: 20945403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
    Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix.
    Siejka A; Schally AV; Block NL; Barabutis N
    BJU Int; 2010 Nov; 106(9):1382-8. PubMed ID: 20151966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Frans Debruyne, Arkadij A. Gres, Dmitrii L. Arustamov. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist Cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-80.
    Drewa T; Chlosta P
    Eur Urol; 2009 Feb; 55(2):e36-7; author reply e38-9. PubMed ID: 18703271
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
    Pinski J; Lamharzi N; Halmos G; Groot K; Jungwirth A; Vadillo-Buenfil M; Kakar SS; Schally AV
    Endocrinology; 1996 Aug; 137(8):3430-6. PubMed ID: 8754771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.
    Rozsa B; Nadji M; Schally AV; Dezso B; Flasko T; Toth G; Mile M; Block NL; Halmos G
    Prostate; 2011 Apr; 71(5):445-52. PubMed ID: 20859992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.
    Comaru-Schally AM; Brannan W; Schally AV; Colcolough M; Monga M
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3826-31. PubMed ID: 9814453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.
    Horvath JE; Toller GL; Schally AV; Bajo AM; Groot K
    Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4996-5001. PubMed ID: 15044692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of LHRH antagonist cetrorelix in crossover conditioned media from epithelial (BPH-1) and stromal (WPMY-1) prostate cells.
    Siejka A; Schally AV; Barabutis N
    Horm Metab Res; 2014 Jan; 46(1):21-6. PubMed ID: 23839655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia.
    Debruyne F; Tzvetkov M; Altarac S; Geavlete PA
    Urology; 2010 Oct; 76(4):927-33. PubMed ID: 20932411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
    Bastian PJ
    Eur Urol; 2008 Jul; 54(1):179-80. PubMed ID: 18417273
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
    Speakman MJ
    Eur Urol; 2008 Jul; 54(1):178-9. PubMed ID: 18417272
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
    Ficarra V; Novara G
    Eur Urol; 2008 Jul; 54(1):178. PubMed ID: 18417274
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats.
    Kovacs M; Schally AV
    Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12197-202. PubMed ID: 11593037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bushen Huoxue Fang promotes the apoptosis of epithelial cells in the prostatic ductal system of rats with benign prostatic hyperplasia].
    Sun J; Li QF; Tian DZ; Jiang SB; Wu XD; Qiu SA; Ren XG; Li YB
    Zhonghua Nan Ke Xue; 2014 Sep; 20(9):824-9. PubMed ID: 25306812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat.
    Shimizu S; Shimizu T; Tsounapi P; Higashi Y; Martin DT; Nakamura K; Honda M; Inoue K; Saito M
    PLoS One; 2015; 10(8):e0133798. PubMed ID: 26308715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats.
    Funahashi Y; Wang Z; O'Malley KJ; Tyagi P; DeFranco DB; Gingrich JR; Takahashi R; Majima T; Gotoh M; Yoshimura N
    Prostate; 2015 Mar; 75(4):381-9. PubMed ID: 25451715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
    Lamharzi N; Halmos G; Jungwirth A; Schally AV
    Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.